← Leaderboards
Jose M Mejia Oneto
Shasqi, Inc.
$7,281,939
Attributed
$9,828,841
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,828,841 · 8
By mechanism
R44$9,308,463 · 6
R43$520,378 · 2
Top collaborators
- Jesse Mischa Mcfarland5 shared
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseSiteCyclooctenesInjectableInjectionsTumorDoxorubicinReactionPharmaceutical PreparationsSide EffectChemistryMortalityAttenuatedToxic EffectDrug KineticsSafetySystemic ToxicityDesignSolid NeoplasmLocationSodium HyaluronateChemotherapyTissuesMalignant Neoplasms
Grant awards (13)
CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry$1,094,189
R44 · FY2025 · CA · contact PI
Antigen-targeted activation of Topo1 inhibitors via click chemistry$431,859
R44 · FY2025 · CA · contact PI
Antigen-targeted activation of Topo1 inhibitors via click chemistry$1,568,070
R44 · FY2024 · CA · contact PI
Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry$1,217,955
R44 · FY2024 · CA · contact PI
Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma$322,142
R44 · FY2024 · CA · contact PI
Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry$781,732
R44 · FY2023 · CA · contact PI
Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma$298,843
R44 · FY2023 · CA · contact PI
Immune Biomarker Assessment and Manufacturing Development for SQ3370-001, a first-in-human phase I dose-escalation clinical trial to test a novel treatment against advanced solid tumors$801,129
R44 · FY2022 · CA · contact PI
Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma$1,376,786
R44 · FY2021 · CA · contact PI
Immune Biomarker Assessment and Manufacturing Development for SQ3370-001, a first-in-human phase I dose-escalation clinical trial to test a novel treatment against advanced solid tumors$1,198,848
R44 · FY2021 · CA · contact PI
Material-guided delivery and local activation of bioorthogonal prodrugs$216,910
R44 · FY2019 · GM · contact PI
Material guided drug delivery for pigmented villonodular synovitis using an implantable biomaterial and bio-orthogonal chemistry$295,394
R43 · FY2018 · CA · contact PI
Using implantable biomaterial and bio-orthogonal chemistry to guide delivery of antibiotics$224,984
R43 · FY2016 · GM · contact PI